328130.KQ Lunit Inc.
- Market cap
- KRW 1.17T
- P/E
- -
- P/B
- 3.52x
- ROE
- -24.9%
- Dividend yield
- -
- Fundamental score
- 1.4/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 328130.KQ undervalued?
Graham numberThe Graham number of Lunit Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lunit Inc. fundamental analysis
6 of 21 checks passedROE 0/2
Low return on equity (-24.9%), below 10%.
ROA 0/1
Return on assets (-15.2%) is below the industry median (6.2%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (73.5%) is above the industry median (0.5%).
Revenue Growth 2/2
Revenue grew 81.7% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 2/2
Cash covers 3.2 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (3.5x) is above the industry median (0.7x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Lunit Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lunit Inc.
Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predi…
Full company profileLunit Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Lunit Inc. annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 198M | 1.43B | 6.64B | 13.9B | 25.1B | 54.2B | 83.1B | 91.5B |
| Gross Profit | - | 1.37B | 5.88B | 13.7B | 25.0B | 53.9B | 83.1B | 91.5B |
| Operating Income | -11.6B | -21.0B | -45.7B | -50.7B | -42.2B | -67.7B | -83.1B | -57.9B |
| EBITDA | - | - | - | -34.9B | -31.0B | -61.8B | -10.8B | -37.9B |
| Net Income | -47.0B | -83.7B | -73.7B | -39.1B | -36.8B | -82.4B | -47.4B | -82.7B |
| EPS | -4,465 | -3,841 | -3,379 | -1,544 | -1,282 | -2,855 | -757 | -1,112 |
| Balance Sheet | ||||||||
| Total Assets | 38.4B | 25.1B | 93.8B | 97.2B | 268B | 435B | 370B | 545B |
| Total Liabilities | 97.3B | 156B | 91.8B | 28.2B | 32.8B | 270B | 232B | 214B |
| Shareholders' Equity | -58.9B | -131B | 2.04B | 68.9B | 235B | 165B | 137B | 332B |
| Cash & Short-term Investments | 36.6B | 20.9B | 86.7B | 61.2B | 222B | 52.4B | 14.1B | 155B |
| Cash Flow | ||||||||
| Operating Cash Flow | -10.00B | -16.8B | -32.7B | -53.0B | -36.5B | -65.7B | -55.2B | -43.7B |
| Capital Expenditure | 416M | 846M | 753M | 3.96B | 1.59B | 6.67B | 9.63B | 4.96B |
| Free Cash Flow | - | -17.6B | -33.5B | -57.0B | -38.1B | -72.4B | -64.8B | -48.6B |
| Ratios | ||||||||
| ROE | - | - | -3,615.8% | -56.8% | -15.7% | -50.0% | -34.5% | -24.9% |
| ROA | -122.3% | -333.3% | -78.5% | -40.3% | -13.7% | -18.9% | -12.8% | -15.2% |
| Net Profit Margin | -23,675.0% | -5,855.7% | -1,109.7% | -282.1% | -146.7% | -152.1% | -57.0% | -90.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Lunit Inc. dividends
Lunit Inc. has not paid dividends in the last 7 fiscal years.
Last stock split: 2:1 on May 4, 2026.
Who owns Lunit Inc.
- Insiders 14.31%
- Institutions 12.02%
- Public & others 73.68%
- Shares outstanding 74.5M
- Free float 62.9M
Lunit Inc. company profile
- Company name
- Lunit Inc.
- Ticker
- 328130.KQ
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 307
- Fiscal year end
- December
- Address
- K-Square Gangnam 2, Seoul, South Korea
- Phone
- 82 2 2138 0827
- Website
- lunit.io
About Lunit Inc.
Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations; with Agilent Technologies Inc. to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development; with Daiichi Sankyo Company, Limited to accelerate biomarker discovery and translational research; and with Summit Therapeutics Inc. to apply AI-powered SCOPE IO pathology platform for tumor microenvironment analysis in immuno-oncology development. Lunit Inc. was founded in 2013 and is based in Seoul, South Korea.
Lunit Inc. management
10- Mr. Anthony Seungwook PaekCo-Founder & Executive Chairman
- Mr. Beomseok Brandon SuhCEO & Director
- Mr. Jungin LeeCo-Founder & Dept Head of Infrastructure of Technology Innovation Group
- Mr. Donggeun YooCo-founder, Chief AI Officer of Technology Innovation Group
- Mr. Sunggyun ParkCo-founder and Chief Operating & Regulation Division Officer
- Mr. Kyunghyun PaengCo-founder & Chief Product Officer of Oncology Group
- Mr. Hyeonseong ParkChief Financial Officer
- Mr. Jinsub BaeDept. Head of Finance & Accounting
- Mr. Frederik Winther Struve B.Sc., J.D.General Counsel - Lunit International
- Ms. Koren CryerDept. Head of Marketing